Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Gedeon Richter Ltd S/Gdr — Q1 2026 Earnings Presentation
37 slides from Chemical Works Of Gedeon Richter's earnings presentation, May 12, 2026
Slide 1: Q1 2026 Earnings Report
Q1 2026 Earnings Report 12 May 2026
Slide 2: Q1 2026 highlights – an eventful quarter; guidance reiterated
Q1 2026 highlights – an eventful quarter; guidance reiterated High-single-digit guidance Pharma Revenues (CER*) Q1 2026 CER revenue growth was 5.9% growth 2026 1 High-single-digit Q1 2026 CER Clean EBIT growth was 15% Clean EBIT (CER*) growth Q1 HUF 217.3bn HUF 69.8bn HUF 67.4bn 1 EBIT: Profit/loss
Slide 3: Financial and operational highlights
Financial and operational highlights Financial highlights • CER revenue growth was 5.9% in Q1 2026, slightly below the high-single-digit growth guidance for the full year. FX was a major drag on reported revenues, representing more than 7ppt headwind (due to the weak USD and stronger HUF). Hence, re
Slide 4: Access to health via innovative and affordable solutions
Access to health via innovative and affordable solutions Selected KPIs 5.1mn units emergency ~120,000 patients reached contraceptives distributed 3.4mn total cariprazine TRx 9 successful clinical studies with Ryeqo® via two NGO partners (US, 2025) (GenMed, 2025) (since launch) (Africa and Sri Lanka,
Slide 5: Financial Highlights
Financial Highlights 5 5
Slide 6: Q1 2026 CER revenues +5.9%; BIO, Vraylar ahead, GM behind plans
Q1 2026 CER revenues +5.9%; BIO, Vraylar® ahead, GM behind plans Key messages • WHC sales growth (+6% CER) was affected by the timing of deliveries (some contraception sales Revenues Reported CER in APAC likely to be realized later this year; some Q1 2026 pre-shipments affected EEU/CEU revenues). Th
Slide 7: Very strong FX headwind - reported revenues declined 1% in Q1
Very strong FX headwind - reported revenues declined 1% in Q1 Pharmaceutical Revenues, cumulative (HUF bn), reported Pharmaceutical Revenues by region (HUF bn) -1.3% Western Europe 41.6 220.1 217.3 45.9 13.1 2.9 16.7 1.3 Central Europe 46.1 44.7 65.5 57.7 Pharma other Eastern Europe 43.8 39.1 BIO No
Slide 8: FX trends hurt CoGS, help Opex; efficiency measures at play
FX trends hurt CoGS, help Opex; efficiency measures at play Operating costs as a % of Pharma revenues (%) Operating expenses (pharma) (HUFbn) S&M R&D G&A 35 33 32 31 31 90.5 30 30 30 30 30 30 81.9 83.1 76.9 16.3 76.1 73.8 74.7 73.9 25 14.1 14.3 70.8 21 20 12.5 13.3 12.9 12.6 13.4 19 19 18 18 13.5 20
Slide 9: Strong CER Clean EBIT growth of 15% on Vraylar and BIO
Strong CER Clean EBIT growth of 15% on Vraylar® and BIO Pharmaceutical Clean EBIT, cumulative (HUF bn) Key messages Q1 2025 Q1 2026 • CER Clean EBIT growth was a remarkable 15% in Q1 YoY. 68.7 69.7 FX was a massive headwind in Q1 2026 (continued trend of 12.0 1.1 weaker USD, stronger HUF), consequen
Slide 10: Below-the-line: taxes offset net financial income; no unusual items
Below-the-line: taxes offset net financial income; no unusual items Net Profit in Q1 2026, below-Clean EBIT items (HUF bn) Including HUF 1.3bn Includes taxes calculated in line restructuring expenses 0.9 with Global Minimum Tax 2.5 3.0 69.8 -13.3 -2.4 67.4 5.0 65.3 -0.2 Clean EBIT Non-recurring EBIT
Slide 11: Sustained robust cash generation in Q1 2026
Sustained robust cash generation in Q1 2026 Free Cash Flow in Q1 2026 (HUF bn) Key messages No material change • Free Cash Flow was HUF 77bn in Q1 2026, Application of Cash Flow in NWC in Q1 2026 rising by 29% YoY on the back of stronger operating cash flows and no increase in 76.4 77.4 77.0 0.9 3.1
Slide 12: Research and Development
Research and Development R&D 12 12
Slide 13: R&D pipeline – changes during Q1 2026
R&D pipeline – changes during Q1 2026 Market Preclinical phase Clinical phase Regulatory & Launch Phase 1 Phase 2 Phase 3 Own Technology Development Clinical phase Neuropsychiatry Biotechnology Women’s Healthcare Own RSL* General Medicines new discontinued License 13 * Ready-to-Sell Licensed pipelin
Slide 14: Neuropsychiatry
Neuropsychiatry CNS 14 14
Slide 15: CNS revenues were up 4% despite unfavorable FX trends
CNS CNS revenues were up 4% despite unfavorable FX trends CNS | HUF mn Q1 2025 Q1 2026 Ch. % YoY Revenue (HUFbn) Revenues 59 785 62 155 4 Cost of Sales -432 -430 0 +4.0% Gross Profit 59 353 61 725 4 +4.0% Gross Margin % 99.3 99.3 73.2 67.1 59.8 62.2 Sales & Marketing -912 -1 171 28 64.6 62.2 59.8 G&
Slide 16: Vraylar: strong, double-digit prescription growth
CNS Vraylar®: strong, double-digit prescription growth Vraylar® Key messages • Vraylar® royalty income reached HUF 59bn in Q1 +4.4% +4.4% 2026, up 4.4% YoY affected by the weak USD 68.9 56.2 58.7 and the strong HUF 64.1 60.7 58.7 56.2 49.4 • Global Vraylar® sales were USD 905mn, up by 18.4%, reflect
Slide 17: Women's Healthcare
Women’s Healthcare WHC 17 17
Slide 18: Sales in Q1 affected by shipments, FX; R&D engine at full speed
WHC Sales in Q1 affected by shipments, FX; R&D engine at full speed WHC | HUF mn Q1 2025 Q1 2026 Ch. % YoY Revenue (HUFbn) Revenues 78 844 79 385 1 Cost of Sales -24 918 -29 737 19 +0.7% Gross Profit 53 926 49 648 -8 +0.7% Gross Margin % 68.4 62.5 89.9 79.4 78.8 Sales & Marketing -26 504 -22 915 -14
Slide 19: Menopause and UF/EM growth vs. temporarily weaker OCs in Q1
WHC Menopause and UF/EM growth vs. temporarily weaker OCs in Q1 Total WHC revenues by therapeutic areas (quarterly, HUF bn) Key messages Performance of the fast-growing focus TAs were overall in line +0.7% 89.9 with expectations in Q1 2026. Uterine Fibroids (UF)/Endometriosis Other WHC 7.6 84.3 79.4
Slide 20: Ryeqo outstanding; Lenzetto grows on an expanding market
WHC | Ryeqo® outstanding; Lenzetto® grows on an Highlighted brands expanding market Ryeqo® Lenzetto® +63.8% +36.2% 10.7 6.1 9.6 5.6 8.7 5.1 7.4 4.4 6.5 3.7 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 +63.8% +36.2% 10.7 5.1 3.7 6.5 2.3 3.2 Q1 2024 Q1 2025 Q1 2026 Q
Slide 21: Solid Drovelis growth; steady EVRA and Bemfola
WHC Highlighted brands | Solid Drovelis® growth; steady EVRA® and Bemfola® EVRA® Drovelis® Bemfola® -0.5% +25.8% -5.1% 10.1 7.8 7.8 5.3 5.1 9.6 4.9 5.0 7.0 8.2 8.1 8.1 6.6 6.2 3.6 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Slide 22: Biotechnology
Biotechnology BIO 22 22
Slide 23: Increasing revenues, sustained margins and lower R&D in Q1 2026
BIO Increasing revenues, sustained margins and lower R&D in Q1 2026 BIO | HUF mn Q1 2025 Q1 2026 Ch. % YoY Revenue (HUFbn) Revenues 13 060 16 721 28 Cost of Sales -8 357 -10 596 27 +28.0% Gross Profit 4 703 6 125 30 +28.0% 21.0 Gross Margin % 36.0 36.6 16.7 Sales & Marketing -2 123 -2 589 22 16.4 16
Slide 24: Strong teriparatide shipments, continued CDMO revenue fluctuation
BIO Strong teriparatide shipments, continued CDMO revenue fluctuation Teriparatide Key messages +40.1% +40.1% • Teriparatide biosimilar (incl. Terrosa®) revenues reached record highs and were up 8.5 8.4 8.6 8.6 7.7 by 40% Q1 YoY, slightly higher than in Q4 6.1 6.1 6.1 2025. Revenue growth was driven
Slide 25: General Medicines
General Medicines GM 25 25
Slide 26: A challenging start to the year with external headwinds
GM A challenging start to the year with external headwinds GM | HUF mn Q1 2025 Q1 2026 Ch. % YoY Revenue (HUFbn) Revenues 65 541 57 702 -12 Cost of Sales -29 349 -28 599 -3 -12.0% Gross Profit 36 192 29 103 -20 -12.0% Gross Margin % 55.2 50.4 65.5 65.3 65.1 65.5 Sales & Marketing -14 422 -13 317 -8
Slide 27: Blood&metab driven by launches, Pain recovers, OTC suffers
GM Blood&metab driven by launches, Pain recovers, OTC suffers Total GenMed revenues by therapeutic areas (quarterly, HUF bn) Key messages -12.0% • Blood & metabolic category saw timely launch of Blood&metabolic 65.5 65.3 65.1 Rivaroxaban in wave-2 CEE countries. Dabigatran brands 4.6 4.9 4.9 57.7 ho
Slide 28: Appendix
Appendix @ GEDEON RICHTER
Slide 29: Net financial income in Q1 2026 on some FX gain, net interest
Net financial income in Q1 2026 on some FX gain, net interest Diff Q1 Q1 2025 Q1 2026 -8.0 Unrealised exchange (loss)/gain 14.1 6.1 3.0 Realised exchange (loss)/gain -4.1 -1.1 Result of realised & unrealised -1.1 1.1 0.0 forward exchange contracts 1.4 Interest income / (Interest expense) 1.6 3.0 1.8
Slide 30: Business units' P&L in Q1 2026
Business units’ P&L in Q1 2026 Pharma Pharma Q1 2026 WHC CNS BIO GM Other Eliminations Group total other total Revenues 79.4 62.2 16.7 57.7 1.3 217.3 5.5 -2.6 220.2 Cost of Sales -29.7 -0.4 -10.6 -28.6 -1.1 -70.4 -4.4 2.6 -72.2 Gross Profit 49.6 61.7 6.1 29.1 0.3 146.9 1.2 0.0 148.0 Sales & Marketin
Slide 31: Strategic positioning and vision of the business units
Strategic positioning and vision of the business units Pharma | Pharmaceuticals segment Name of the Business Units Brief description Key strategic goal Therapeutic areas Leveraging our world class early phase R&D capability Maximize the potential of cariprazine, while developing in the central nervo
Slide 32: Consolidated Income Statement
Consolidated Income Statement 2025 Q1 2026 Q1 2025 Change Consolidated P&L HUFm HUFm HUFm % 928 962 Revenues 220 202 224 024 -1.7% 259 719 of which royalty 61 324 58 542 4.8% (288 051) Cost of Sales (72 450) (68 854) 5.2% 640 911 Gross Profit 147 752 155 170 -4.8% (166 128) Sales & marketing expense
Slide 33: Consolidated Balance Sheet - ASSETS
Consolidated Balance Sheet - ASSETS 31 March 2026 31 Dec 2025 Change Consolidated Balance Sheet HUFm HUFm % ASSETS 1 761 213 1 698 220 3.7% Non-current assets 919 973 918 967 0.1% Property, plant and equipment 379 196 383 667 -1.2% Goodwill 43 124 42 155 2.3% Other intangible assets 290 251 293 428
Slide 34: Consolidated Balance Sheet - EQUITY AND LIABILITIES
Consolidated Balance Sheet - EQUITY AND LIABILITIES 31 March 2026 31 Dec 2025 Change Consolidated Balance Sheet HUFm HUFm % EQUITY AND LIABILITIES 1 761 213 1 698 220 3.7% Capital and reserves 1 460 347 1 400 889 4.2% Share capital 18 638 18 638 0.0% Treasury shares (34 118) (34 021) 0.3% Share prem
Slide 35: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement 2025 Q1 2026 Q1 2025 Change Consolidated cash flow HUFm HUFm HUFm % Operating activities 284 747 Profit before income tax 78 782 81 980 -3.9% 60 463 Depreciation and amortisation 16 102 14 053 14.6% 9 690 Non cash items (5 097) (9 038) -43.6% (5 402) Net interest and
Slide 36: Contacts, Financial calendar, Investor relations manager
Contacts Financial calendar Company name: Gedeon Richter Plc. | 12 May 2026 – Q1 2026 results Sector: Pharmaceutical | 7 August 2026 – Q2/H1 2026 results Company address: 1103 Budapest, Gyömrői street 19-21., Hungary | 10 November 2026 – Q3/Q1-Q3 2026 results Telephone: +36 1 431 5764 Investor relat
Slide 37: Disclaimer
Disclaimer This presentation may contain forward-looking statements, that may include, but are not limited to, those regarding capital, investment, cash flows, demand, earnings, efficiency, production, profits. These forward-looking statements are subject to risks, uncertainties, and other factors,
Gedeon Richter Ltd S/Gdr — Q1 2026 Earnings Presentation on 6ix